BioNTech and OncoC4 report PRESERVE-003 stage 1 OS results
BioNTech SE and OncoC4 Inc. released first median overall survival results from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart, reporting nearly doubled survival versus standard chemotherapy in a specific patient population and citing a stock jump of about 2%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.